Amy E. Juedes

Array ( [id] => 17503513 [patent_doc_number] => 20220096615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL DYSFUNCTION [patent_app_type] => utility [patent_app_number] => 17/324188 [patent_app_country] => US [patent_app_date] => 2021-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17324188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18266143 [patent_doc_number] => 20230087385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => Use of SAA, rSAA or inhibitors of SAA in the treatment of dysregulated inflammation [patent_app_type] => utility [patent_app_number] => 17/999081 [patent_app_country] => US [patent_app_date] => 2021-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6018 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17065851 [patent_doc_number] => 20210268066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => METHODS AND KITS FOR TREATING PAIN [patent_app_type] => utility [patent_app_number] => 17/317333 [patent_app_country] => US [patent_app_date] => 2021-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16935 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17317333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18673105 [patent_doc_number] => 20230310581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => A LIVE ATTENUATED MEASLES VIRUS VECTORED VACCINE FOR SARS-COV-2 [patent_app_type] => utility [patent_app_number] => 17/905962 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30270 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17213143 [patent_doc_number] => 20210346479 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => THERAPEUTIC CANCER VACCINES DERIVED FROM A NOVEL DENDRITIC CELL LINE [patent_app_type] => utility [patent_app_number] => 17/239097 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7420 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17239097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18418597 [patent_doc_number] => 20230173055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => INFLUENZA VIRUS SURFACE PROTEIN-DERIVED RECOMBINANT HEMAGGLUTININ PROTEIN FORMING TRIMER, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/995872 [patent_app_country] => US [patent_app_date] => 2021-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12344 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19256880 [patent_doc_number] => 12016909 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => Regulatory T cell epitopes, compositions and uses thereof [patent_app_type] => utility [patent_app_number] => 17/236534 [patent_app_country] => US [patent_app_date] => 2021-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 22127 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17236534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18836769 [patent_doc_number] => 11844826 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-19 [patent_title] => Regulatory T cell epitopes, compositions and uses thereof [patent_app_type] => utility [patent_app_number] => 17/236463 [patent_app_country] => US [patent_app_date] => 2021-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 22100 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17236463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18362469 [patent_doc_number] => 20230144060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => MERS-CoV VACCINE [patent_app_type] => utility [patent_app_number] => 17/918244 [patent_app_country] => US [patent_app_date] => 2021-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17918244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170402 [patent_doc_number] => 20210324072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => ANTIBODIES TO TIGIT [patent_app_type] => utility [patent_app_number] => 17/227642 [patent_app_country] => US [patent_app_date] => 2021-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48839 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17227642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18691029 [patent_doc_number] => 20230321218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => SARS-COV2 CORONAVIRUS RECONSTITUTED RBM AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/995733 [patent_app_country] => US [patent_app_date] => 2021-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483676 [patent_doc_number] => 20230210978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => A UNIVERSAL ADOPTIVE IMMUNOTHERAPY APPROACH TO TREAT COVID-19 AND FUTURE EMERGING INFECTIOUS DISEASES [patent_app_type] => utility [patent_app_number] => 17/995008 [patent_app_country] => US [patent_app_date] => 2021-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14776 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18375990 [patent_doc_number] => 20230151072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => MASKED IL-2 CYTOKINES AND THEIR CLEAVAGE PRODUCTS [patent_app_type] => utility [patent_app_number] => 17/995163 [patent_app_country] => US [patent_app_date] => 2021-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65558 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -145 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18496186 [patent_doc_number] => 20230218741 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => SARS-COV-2 VACCINES FOR POPULATION-SCALE IMMUNITY [patent_app_type] => utility [patent_app_number] => 17/915986 [patent_app_country] => US [patent_app_date] => 2021-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17915986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18964181 [patent_doc_number] => 11897932 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Receptors for ligand-dependent transcriptional regulation [patent_app_type] => utility [patent_app_number] => 17/217635 [patent_app_country] => US [patent_app_date] => 2021-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 21547 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17217635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170662 [patent_doc_number] => 20210324332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => EX VIVO USE OF MODIFIED CELLS OF LEUKEMIC ORIGIN FOR ENHANCING THE EFFICACY OF ADOPTIVE CELL THERAPY [patent_app_type] => utility [patent_app_number] => 17/213461 [patent_app_country] => US [patent_app_date] => 2021-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45328 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17213461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18994597 [patent_doc_number] => 11911414 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-27 [patent_title] => Regulatory T cell epitopes [patent_app_type] => utility [patent_app_number] => 17/214061 [patent_app_country] => US [patent_app_date] => 2021-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 38 [patent_no_of_words] => 60419 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17214061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17124456 [patent_doc_number] => 20210299224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => Methods and Compositions for Treating Autoimmune and Inflammatory Conditions [patent_app_type] => utility [patent_app_number] => 17/301123 [patent_app_country] => US [patent_app_date] => 2021-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17301123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156155 [patent_doc_number] => 20210317206 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/206407 [patent_app_country] => US [patent_app_date] => 2021-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 76023 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17206407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156156 [patent_doc_number] => 20210317207 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/206550 [patent_app_country] => US [patent_app_date] => 2021-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17206550 [rel_patent_id] =>[rel_patent_doc_number] =>)